Knockdown of survivin results in inhibition of epithelial to mesenchymal transition in retinal pigment epithelial cells by attenuating the TGFβ pathway
Creators
- 1. Department of Anatomy, Histology and Embryology, Fudan University, Shanghai (China)
- 2. Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, 38163 (United States)
- 3. Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN, 38163 (United States)
- 4. Department of Genetics, University of Tennessee Health Science Center, Memphis, TN, 38163 (United States)
- 5. Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163 (United States)
Description
Highlights: • TGFβ activates BIRC5 expression in RPE cells. • Knockdown of BIRC5 results in the suppression of EMT in RPE cells. • Reduction of survivin attenuates TGFβ pathway in RPE cells. • Inhibition of TGFβ pathway downregulates survivin expression in RPE cells. Proliferative vitreoretinopathy (PVR) is a common complication of open globe injury and the most common cause of failed retinal detachment surgery. The response by retinal pigment epithelial (RPE) cells liberated into the vitreous includes proliferation and migration; most importantly, epithelial to mesenchymal transition (EMT) of RPE plays a central role in the development and progress of PVR. For the first time, we show that knockdown of BIRC5, a member of the inhibitor of apoptosis protein family, using either lentiviral vector based CRISPR/Cas9 nickase gene editing or inhibition of survivin using the small-molecule inhibitor YM155, results in the suppression of EMT in RPE cells. Knockdown of survivin or inhibition of survivin significantly reduced TGFβ-induced cell proliferation and migration. We further demonstrated that knockdown or inhibition of survivin attenuated the TGFβ signaling by showing reduced phospho-SMAD2 in BIRC5 knockdown or YM155-treated cells compared to controls. Inhibition of the TGFβ pathway using TGFβ receptor inhibitor also suppressed survivin expression in RPE cells. Our studies demonstrate that survivin contributes to EMT by cross-talking with the TGFβ pathway in RPE cells. Targeting survivin using small-molecule inhibitors may provide a novel approach to treat PVR disease.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.bbrc.2018.03.021Additional details
Identifiers
- DOI
- 10.1016/j.bbrc.2018.03.021;
- PII
- S0006291X18304959;
Publishing Information
- Journal Title
- Biochemical and Biophysical Research Communications
- Journal Volume
- 498
- Journal Issue
- 3
- Journal Page Range
- p. 573-578
- ISSN
- 0006-291X
- CODEN
- BBRCA9
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 54056542
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- CELL PROLIFERATION; INJURIES; RECEPTORS; RHODOPSIN; SURGERY
- Descriptors DEC
- DISEASES; MEDICINE; MEMBRANE PROTEINS; ORGANIC COMPOUNDS; PIGMENTS; PROTEINS
Optional Information
- Copyright
- Copyright (c) 2018 Elsevier Inc. All rights reserved.